Search - tctmd.com

Displaying 281 - 300 of 388

Sort: Relevancy | Date

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

Presenter: Suhas Lele

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Patrick Serruys

October 25, 2012

Presentation TCT 2012

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

Presenter: Sunao Nakamura

October 23, 2012

Presentation TCT 2012

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

Presenter: Lamin King

October 23, 2012

Presentation TCT 2012

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

Presenter: Patrick Serruys

October 23, 2012

Presentation TCT 2012

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Presenter: Run-Lin Gao

October 23, 2012

Presentation TCT 2012

Sirolimus-Eluting Stent (Svelte Medical) Program Update

Presenter: Mark Webster

October 23, 2012

Presentation TCT 2012

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

Presenter: David Kandzari

October 23, 2012

Presentation TCT 2012

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Presenter: Masato Nakamura

October 22, 2012

News Daily News

Stent Fractures Persist Among Newer-Generation Devices

Jason Kahn

October 02, 2012

News Daily News

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

Jason Kahn

October 02, 2012

News Daily News

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

Yael L. Maxwell

September 07, 2012

News Daily News

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

Yael L. Maxwell

September 07, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

News Daily News

SORT OUT III: Riesgo más alto de trombosis del stent muy tardía con Cypher en comparación con Endeavor

L.A. McKeown

August 23, 2012

News Daily News

SORT OUT III: Higher Risk of Very Late Stent Thrombosis with Cypher vs. Endeavor

L.A. McKeown

August 23, 2012

Advertisement

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

First-in-Man Results with a Novel Nanoparticle-Based Sirolimus-Coated Balloon in Coronary In-Stent Restenosis Lesions (Concept Medical)

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

LEADERS 5-Year: A Prospective, Randomized Trial of Bioabsorbable Polymer-based Biolimus-Eluting vs. Sirolimus-Eluting Stents

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

TCT-48. Two Year Follow-up and Sub-group Analysis of a Polymer-free Sirolimus- and Probucol-eluting Stent vs. A New Generation Zotarolimus-eluting Stent in Coronary Artery Disease

TCT-44. LEADERS: 5-Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable...

TARGET I: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs an Everolimus-Eluting Stent (MicroPort)

Sirolimus-Eluting Stent (Svelte Medical) Program Update

DESSOLVE II: A Prospective, Randomized Trial of a Biodegradable Polymer-based Sirolimus-Eluting Stent vs a Zotarolimus-Eluting Stent (Micell)

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Stent Fractures Persist Among Newer-Generation Devices

Las Fracturas del Stent Persisten en los Dispositivos de Nueva Generación

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

SORT OUT IV: El Xience Aguanta el Tirón del Cypher en la Prevención de la Trombosis del Stent

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

SORT OUT III: Riesgo más alto de trombosis del stent muy tardía con Cypher en comparación con Endeavor

SORT OUT III: Higher Risk of Very Late Stent Thrombosis with Cypher vs. Endeavor

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content